Arsenic Trioxide in Treating Patients With Multiple Myeloma

Stopped early · Phase 2

Conditions studied: Multiple Myeloma and Plasma Cell Neoplasm

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have relapsed or refractory stage II or stage III multiple myeloma.

Key facts

Study ID

NCT00017433

Run by

CTI BioPharma

Starts

2001-01-01

Expected to finish

2005-01-01

Last updated by the study team

2020-10-06

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Scripps Clinic — La Jolla, California, United States
• Rocky Mountain Cancer Center — Denver, Colorado, United States
• Georgia Cancer Specialist — Marietta, Georgia, United States
• University of Illinois at Chicago — Chicago, Illinois, United States
• Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio, United States
• Swedish Cancer Institute — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.